A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection

Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Ribaxamase (Primary)
  • Indications Clostridium infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Synthetic Biologics
  • Most Recent Events

    • 03 Aug 2017 According to a Synthetic Biologics media release, data from the study will be presented at the Infectious Disease Week 2017.
    • 03 Aug 2017 According to a Synthetic Biologics media release, the company expects to share additional results from several exploratory endpoints from the study in the second half of 2017.
    • 11 May 2017 According to a Synthetic Biologics media release, U.S. Food and Drug Administration (FDA) has granted a breakthrough therapy designation for SYN-004 (ribaxamase) for prevention of Clostridium difficile infection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top